BioCentury
ARTICLE | Distillery Therapeutics

Cancer

May 15, 2018 6:09 PM UTC

Cell culture studies suggest inhibiting KIF15 alone or in combination with KSP could help treat cancer. In HeLa cells, a tool compound KIF15 inhibitor decreased proliferation compared with no treatment, and the KIF15 inhibitor plus the KSP inhibitor filanesib or a tool compound KSP inhibitor synergistically decreased proliferation compared with any agent alone. Next steps include identifying and testing KIF15 inhibitors alone or in combination with KSP inhibitors in models of cancer.

Array BioPharma Inc. has filanesib (ARRY-520), a KSP inhibitor, in Phase II testing to treat multiple myeloma (MM)...